| Document |
Document Title |
|
WO/1999/062877A1 |
A process for producing a purified prostaglandin derivative having a high purity which comprises adding an alkene (1) to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reactant to give an adduct; reacting t...
|
|
WO/1999/061029A1 |
A sleep inducing agent comprising, as an active component, a prostaglandin derivative represented by formula (1), wherein X represents a halogen atom, Y represents a group represented by (CH¿2?)¿m?, a cis-vinylene group or a phenylene ...
|
|
WO/1999/061419A1 |
A prostaglandin derivative represented by formula (I) wherein X represents a halogen atom, n is an integer of 1 to 5, R?1¿ represents a C¿3-10? cycloalkyl group, a C¿3-10? cycloalkyl group substituted with a C¿1-4? alkyl group, a C¿...
|
|
WO/1999/050241A1 |
The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I): wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, W, X, Z, a, b, and p are defined...
|
|
WO/1999/050242A1 |
The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, W, X, Z, a, b, p and q are define...
|
|
WO/1999/044990A1 |
The invention relates to novel process for the preparation of prostaglandin compounds which are useful as medicaments.
|
|
WO/1999/033794A1 |
$g(v)-Cycloalkyl-prostaglandin E¿2? derivatives of formula (I) (wherein all symbols are as defined in the description); and non-toxic salts thereof, prodrugs thereof and cyclodextrin clathrates thereof. Compounds of formula (I) strongly...
|
|
WO/1999/032441A1 |
13-Oxa analogs of certain prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
WO/1999/025358A1 |
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The compounds used in accordance with the invention are represented by formula (I), wherein wavy line attachments indicate either the alpha ...
|
|
WO/1999/021830A1 |
An improved method is described for making 9-deoxy-PGF¿1?-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.
|
|
WO/1999/012898A1 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to formula (I): wherein R¿1?, R¿2?, R¿3?, R¿4?, X, and Z are as defined. This invention also includes op...
|
|
WO/1999/012897A1 |
It has been surprisingly discovered that the disadvantages of the lengthy literature procedures to synthesize 13,14-dihydro prostaglandin A, E, and F derivatives can be overcome using a novel Methyl 7-(2-hydroxy-5-(2-(2-oxiranyl)ethyl)-4...
|
|
WO/1999/012895A1 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to formula (A), wherein R¿1?, R¿2?, R¿3?, R¿4?, X, Y and Z are defined below. This invention also includ...
|
|
WO/1999/012899A1 |
Described is a process for making prostaglandin F analogs, the process comprising the steps of: I) preparing an intermediate having a structure according to Formula (A): wherein R?6¿ and R?7¿ are as defined in the specification; wherei...
|
|
WO/1999/012896A1 |
The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4?, X, Y, and Z are defined below. This invention also includ...
|
|
WO/1998/058911A2 |
This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonist...
|
|
WO/1998/058910A1 |
Compounds of the general formula A-X¿1?-NO¿2?, or their pharmaceutical compositions, wherein A contains a prostaglandin residue, X¿1? is a bivalent connecting bridge.
|
|
WO/1998/057930A1 |
Keto-substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
WO/1998/052914A1 |
The invention relates to leukotriene B�4? derivatives of general formula (I) in which R�1? stands for CH�2?OH, CH�3?, CF�3?, COOR�4?, CONR�5?R�6?; R�2? stands for H or an organic acid radical with 1-15 C atoms; R�3? s...
|
|
WO/1998/052912A2 |
The invention relates to leukotriene B�4? antagonists of formula (I), a method for the production and the pharmaceutical use thereof.
|
|
WO/1998/052915A2 |
The invention relates to leukotriene B�4? derivatives of general formula (I) in which R�1? stands for H, CF�3?, CH�2?OH; R�2? stands for an organic acid radical; R�3? stands for H, C�1?-C�14?-alkyl, C�3?-C�10?-cycloal...
|
|
WO/1998/052916A1 |
The invention relates to leukotriene B�4? derivatives of general formula (I), wherein R�1? = CH�2?OH, CH�3?, CF�3?, COOR�4?, CONR�5?R�6? and R�2? = H or an organic acid radical with 1-15 C atoms, R�3? = H, C�1?-C�...
|
|
WO/1998/039293A2 |
13-thia prostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising said prostaglandins.
|
|
WO/1998/034916A1 |
11,15-O-Dialkylprostaglandin E derivatives represented by general formula (I) and nontoxic salts or cyclodextrin clathrates thereof. In said formula each symbol has the meaning as defined in the specification. The compounds of general fo...
|
|
WO/1998/021181A2 |
15-fluoro substituted analogs of PGF�2$g(a)? and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
WO/1998/020880A2 |
11-Halo substituted analogs of PGF�2$g(a)? and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
WO/1998/021182A2 |
$i(Cis)-$g(D)?4� analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
WO/1998/021180A1 |
Conformationally rigid aryl prostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising said prostaglandins.
|
|
WO/1998/021179A1 |
Prostaglandins and intermediates thereof can be prepared readily, efficiently and industrially advantageously by separating an (E)-hydroxyvinyltin compound from the (E, Z)-enantiomer thereof prepared by the reaction of a hydroxy-1-algin ...
|
|
WO/1998/012175A1 |
Fluorinated prostaglandin derivatives represented by general formula (1) or salts thereof; and medicines containing the same as the active ingredient, particularly ones to be used for preventing or treating eye diseases. In said formula ...
|
|
WO/1997/045405A1 |
The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by structure formula (I): wherein the hatched segments represent 'alpha'...
|
|
WO/1997/030710A1 |
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl...
|
|
WO/1997/022581A1 |
New process for the preparation of prostaglandin E1 of formula (I) starting from the compound of formula (II).
|
|
WO/1997/009049A2 |
The present invention provides a method of effecting vasodilation, comprising: administering to a warm blooded animal in need of such treatment, an effective amount of a (1,5-inter)aryl prostaglandin derivative represented by formula (I)...
|
|
WO/1997/001534A1 |
Prostaglandins represented by general formula (I), (II) or (III) and inhibitors of cell migration induced by a chemokine which comprise the compound (I) or (II) as the active ingredient, wherein R1 represents C1-10 alkyl, C3-8 cycloalkyl...
|
|
WO/1996/036599A1 |
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by formula (I), wherein wavy line attachments indicate either the ...
|
|
WO/1996/028419A1 |
A process for synthesizing prostaglandin E1, E2 and derivatives thereof is provided. The process is a "one-pot" method in which 2-furyllithium, copper cyanide, a lower alkyllithium reagent and either an (E)-alkenylstannane or a halogenid...
|
|
WO/1996/026891A1 |
A halogen-containing substituted cyclopentene derivative being useful as a novel intermediate for the preparation of prostaglandins useful as drugs and represented by general formula (I) [wherein R is hydrogen, C1-C6 alkyl, C2-C6 alkenyl...
|
|
WO/1996/016935A1 |
Object: to provide a compound having pharmacological properties similar to those of 3-oxa-9-deoxy-9'beta'-chloro-16,17,18,19,20-pentanor-15-cycl
ohexyl-13,14-didehydro-PGF2'alpha', being more easy to purify and handle than the PGF2'alpha...
|
|
WO/1996/010407A1 |
Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostagl...
|
|
WO/1995/026729A1 |
Therapeutically active and physiologically acceptable 11-deoxy or 15-deoxy prostaglandin F2'alpha' derivatives containing a ring substituted omega chain and their use for the preparation of compositions for the treatment of glaucoma or o...
|
|
WO/1995/025520A1 |
Thiosubstituted prostaglandin derivatives and related compounds having general structure (a) useful as intraocular pressure reducing agents; pharmaceutical compositions containing such compounds; and methods of treatment using such compo...
|
|
WO/1995/020563A1 |
Described are pharmacologically active leukotriene B4 derivatives of the general formula I in which R1 is CH2OH, CH3, CF3, COOR4 or CONR5R6, R2 is H or an organic-acid group with 1 to 15 C-atoms, R3 is H, a C1-C14 alkyl group, optionally...
|
|
WO/1995/020562A1 |
The invention concerns leukotriene B4 derivatives of the formula (I), in which R1 is CH2OH, CH3, CF3, COOR5, CONR6R7, or R1 together with R2 is a carbonyl group, R2 and R3, which may be the same or different, are H or an organic-acid gro...
|
|
WO/1995/019964A1 |
The invention relates to (U) trans- 2-[-4(1-hydroxyhexyl) phenyl]-5-oxocyclopentaneheptanoicacid, and ester and unsaturated derivatives thereof, prostaglandin derivatives. More particularly, the present invention concerns compounds of fo...
|
|
WO/1995/019340A1 |
7-Thiaprostaglandins represented by general formula (I), enantiomers thereof, and mixtures thereof, inhibiting cell migration caused by chemokives such as monocyte migration factor MCP-1/MCAF and serving as a remedy for arteriosclerosis,...
|
|
WO/1995/018101A1 |
A prostaglandin derivative represented by general formula (I), a salt thereof, and a medicinal composition containing the same as the active ingredient for lowering the ocular tension. In said formula, R1 represents hydrogen, C1-C10 alky...
|
|
WO/1995/018102A1 |
The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxycyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups...
|
|
WO/1995/011229A1 |
Compounds of formula (I) where the hatched lines indicate alpha ('alpha') configuration, a solid triangle is used to indicate beta ('beta') configuration, lines on both sides of a double bond indicate cis (Z) configuration, and lines on ...
|
|
WO/1995/006634A1 |
9-chloro-prostaglandin derivatives having the formula (I), in which X stands for oxygen or CH2, R1 stands for hydrogen or straight or branched chain alkyl with 1-6 C atoms and A stands for trans-CH=CH- or -CH2-CH2-, are disclosed, as wel...
|
